Insights, Alerts

& Trends

Life Science Industry News

Insights, Alerts & Trends | Life Science IAT Life Science IAT  july 14

Life Science Industry News

Patients still want telehealth, how BioBonds could change the way research is funded, and more.

Top of the News:

Does Your product need a social health-focused campaign to help market it?


A form of financing, called BioBonds, may help get products out of the notorious “translational” testing stage. Now they just have to be signed into legislation, The New York Times reports.


Retired track and field Olympian Gail Devers and biotechnology company Horizon Therapeutics are teaming up in a campaign to spread awareness about thyroid eye disease, FiercePharma writes. Devers, who suffers from thyroid eye disease, speaks in several medias, such as a video and a podcast episode,about her experiences with TED.

According to a study conducted by management consulting firm McKinsey, there’s a strong demand from patients for telehealth post-pandemic: roughly 40% of those surveyed said they would continue to use telehealth in the future, and 40-60% said they would be interested in broader telehealth solutions, Healthcare Finance News reports.


A renewable solvent called Cyrene, produced by green biochemical producer Circa Group may be a cleaner alternative to more toxic materials used in the production of implants and drug delivery systems, Plastics Today writes.

Professional Development:

Here’s how to use gratitude to ground yourself during an intensive time.


The COVID-19 pandemic may have slowed down the mergers and acquisitions market for pharmaceuticals, but analysts from independent investment bank and financial services firm Jefferies claim that a drawdown in biotech stocks could hint at the M&A market picking up, Endpoints writes.


Water filtration and pathogen detection company Nephros has acquired the entirety of the disease monitoring firm GenArraytion, GenomeWeb writes.


The Delaware Court of Chancery ordered medtech provider Hillrom to complete its transaction of the cardiac wearable device company BardyDX after deciding that Hillrom’s reasoning that Medicare price cuts of wearable technology for extended cardiac monitoring did not qualify for a material adverse event that would allow them to leave the deal, Medtech Dive writes. Prices for heart monitoring wearables fell in December of 2020 when no national prices for the technology were established, but the court’s opinion said that that wasn’t enough for BardyDX to leave the deal as it was unknown as to where prices for the technology could end up.